The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.